Frost & Sullivan Looks at the Future of Disease Therapeutics

04-12-2012

Existing adoption rates and commercial success of launched Monoclonal Antibodies (mAbs) for therapeutics have established a strong platform for these products. Broadening the horizontal indications for existing mAbs, expanding the applications of mAbs in new therapeutic areas and developing ...

more

Huge Market Opportunity from Impending Patent Expiry of Blockbuster Biologics

03-22-2012

The expiration of patents and other intellectual property rights of biological innovators over the next decade opens the opportunity for biosimilars to enter the market and increase industry competition. However, biosimilars manufacturers require heavy investments, which are a major barrier ...

more

Emergence of Innovative Treatment Options to Support Improved Compliance and Enhanced Therapeutic Results

03-15-2012

Limited awareness about the disease and its overall occurrence and progression among end-users is hampering the European multiple sclerosis (MS) market. This is being exacerbated by the limited availability of accurate diagnostic tools. There is, therefore, an immediate need for innovative ...

more

Investments from local operators fuelling growth in the private hospitals sector

03-08-2012

Various initiatives by governments of European countries are driving the adoption of IT systems in the healthcare sector. Increasing awareness about healthcare IT across the Middle East and other regions will fuel greater adoption. In Germany, the introduction of health smart cards for every ...

more

Patent Expiry of Blockbuster Drugs worth $150 billion presents lucrative opportunities for generic manufacturers

03-06-2012

While the global generic pharmaceuticals market is expected to peak in 2012 owing to the patent expiry of several leading brands, regulations favouring generics and wider health insurance coverage by Governments and private bodies are expected to boost generic consumption.The Global Generic ...

more

The rise in disease incidence rate boosts demand for innovative therapeutics

02-27-2012

Changing lifestyles, hectic day-to-day activities and unhealthy eating habits have been on the rise over the last decade, directly impacting the health of every individual. These trends prevail in varied proportions across the entire global population. Additionally, the strong prevalence of ...

more

Seamlessly Integrated R&D, Production, Sales and Marketing Processes to Ensure Success in this High Growth Market

02-17-2012

The biosimilars manufacturing industry is at a nascent stage. However, the impending patent expiries of biologics are anticipated to result in the introduction of several new biosimilars and provide impetus to market development.New analysis from Frost & Sullivan, Analysis of European ...

more

02-16-2012

LEUKOCARE has been awarded 2011’s “Biotechnology Investment Opportunity Award”, by the independent research consultancy Frost & Sullivan.In the citation for the 2011 European Biotechnology Industry Early Stage Investment Opportunity Award, Frost & Sullivan focuses on the innovative nature of ...

more

Increasing Incidence of Thrombosis, Paralleled by Maturing Life cycles of Existing Products, Underpin the Demand for Novel Alternatives

02-03-2012

The increasing incidence of thrombosis, paralleled by the maturing life cycles of existing products, are motivating the need for novel alternatives. Establishing end-user confidence and ensuring cost-effectiveness pose significant challenges to market advancement. However, the launch of three ...

more

Technical Expertise, Potential for Time and Cost Savings Underlines Viability of Contract Outsourcing

01-25-2012

Increasingly, big pharma is viewing the outsourcing of pharmaceutical manufacturing as a strategic move that would enable them to focus on their core competencies such as R&D. At the same time, the patent expiry of key blockbuster drugs worth $45 billion and biologics worth $30 billion is ...

more